Journal Of Clinical Oncology Publishes Study Of Cephalon Medication TREANDA Plus Rituximab In Relapsed Non-Hodgkin's Lymphoma

22.08.2008 at 08:00 - Category: Cancer and Oncology

Cephalon, Inc. announced that in a phase 2 study published online today in the Journal of Clinical Oncology, 92 percent of patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma (NHL) responded to treatment with TREANDA(R) (bendamustine hydrochloride) for Injection plus rituximab. This combination study is one of three studies in patients with NHL that Cephalon submitted in December 2007 to the U.S. Food and Drug Administration requesting approval of TREANDA for the treatment of patients with indolent NHL who have progressed during or following treatment with rituximab or a rituximab-containing regimen. TREANDA was approved by the FDA in March 2008 for the treatment of patients with chronic lymphocytic leukemia and is not currently approved for use in NHL.

"A variety of treatment options have been employed in patients with indolent B-cell and mantle cell lymphomas, but resistance to treatment in this patient population often limits effective therapeutic options," said Dr. Charles Morris, Vice President, Worldwide Clinical Research at Cephalon. "Based on what we saw in this study, the combination of TREANDA with rituximab appears to elicit a high rate of durable responses and encouraging progression-free survival."

Original text is here

Plastics Report Reviewed: Agency To Scrutinize Oft-criticized Findings That Chemical Poses Little Risk »»»
OncoVAX, Other Vaccines Provide Hope For Colorectal Cancer Treatment, Prevention »»»
Watson Announces The NDA For A 6-Month Formulation Of Trelstar Accepted For Filing By FDA For The Treatment Of Advanced Prostate Cancer »»»
HPV Virus Helps Cervical And Head And Neck Cancers Resist Treatment And Grow And Spread »»»
Exercise May Protect Against Breast Cancer »»»
Seeking Good Ways To Give Bad News: All Too Often, Doctors Are Insensitive To Patients' Emotional Needs »»»
Zila Demonstrates Effectiveness Of Photosensitizing Agent In Animal Model »»»
Landmark Study Demonstrates Potential Of Radioimmunotherapy For Treatment Of Indolent B-cell Non-hodgkin's Lymphoma »»»
Tamoxifen Chemoprevention Associated With Earlier Diagnosis Of ER-Negative Breast Cancer »»»
Breast Reconstruction Techniques After Mastectomy Depend On Many Factors »»»

'Ray gun' cancer cure nears speed of light

Journal Of Clinical Oncology Publishes Study Of Cephalon Medication TREANDA Plus Rituximab In Relapsed Non-Hodgkin's Lymphoma